Wells Fargo’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-214
| Closed | -$149 | – | 7808 |
|
|
2023
Q4 | $149 | Buy |
214
+11
| +5% | +$6 | ﹤0.01% | 6673 |
|
|
2023
Q3 | $140 | Buy |
203
+44
| +28% | +$56 | ﹤0.01% | 6676 |
|
|
2023
Q2 | $383 | Buy |
159
+1
| +0.6% | +$4 | ﹤0.01% | 6542 |
|
|
2023
Q1 | $1.28K | Buy |
158
+143
| +953% | +$1.9K | ﹤0.01% | 6315 |
|
|
2022
Q4 | $173 | Buy |
15
+1
| +7% | +$11 | ﹤0.01% | 6665 |
|
|
2022
Q3 | $0 | Hold |
14
| – | – | ﹤0.01% | 7653 |
|
|
2022
Q2 | $1K | Buy |
14
+1
| +8% | +$31 | ﹤0.01% | 6668 |
|
|
2022
Q1 | $1K | Hold |
13
| – | – | ﹤0.01% | 6896 |
|
|
2021
Q4 | $1K | Hold |
13
| – | – | ﹤0.01% | 7110 |
|
|
2021
Q3 | $1K | Sell |
13
-1
| -7% | -$73 | ﹤0.01% | 6847 |
|
|
2021
Q2 | $1K | Buy |
14
+2
| +17% | +$122 | ﹤0.01% | 6782 |
|
|
2021
Q1 | $1K | Buy |
12
+3
| +33% | +$234 | ﹤0.01% | 6793 |
|
|
2020
Q4 | $0 | Buy |
9
+3
| +50% | +$133 | ﹤0.01% | 7204 |
|
|
2020
Q3 | $0 | Sell |
6
-1
| -14% | -$59 | ﹤0.01% | 7096 |
|
|
2020
Q2 | $0 | Buy |
7
+1
| +17% | +$34 | ﹤0.01% | 6999 |
|
|
2020
Q1 | $0 | Sell |
6
-21
| -78% | -$891 | ﹤0.01% | 7001 |
|
|
2019
Q4 | $1K | Sell |
27
-758
| -97% | -$36.7K | ﹤0.01% | 6293 |
|
|
2019
Q3 | $39K | Sell |
785
-28
| -3% | -$2.01K | ﹤0.01% | 5632 |
|
|
2019
Q2 | $74K | Buy |
813
+80
| +11% | +$9.7K | ﹤0.01% | 5422 |
|
|
2019
Q1 | $108K | Sell |
733
-34
| -4% | -$6.57K | ﹤0.01% | 5104 |
|
|
2018
Q4 | $121K | Buy |
767
+318
| +71% | +$61K | ﹤0.01% | 5198 |
|
|
2018
Q3 | $110K | Sell |
449
-84
| -16% | -$19.9K | ﹤0.01% | 5318 |
|
|
2018
Q2 | $120K | Buy |
533
+131
| +33% | +$35.1K | ﹤0.01% | 5303 |
|
|
2018
Q1 | $98K | Sell |
402
-1
| -0.2% | -$262 | ﹤0.01% | 5310 |
|
|
2017
Q4 | $124K | Buy |
403
+368
| +1,051% | +$121K | ﹤0.01% | 5217 |
|
|
2017
Q3 | $13K | Sell |
35
-429
| -92% | -$152K | ﹤0.01% | 5817 |
|
|
2017
Q2 | $169K | Buy |
+464
| New | +$139K | ﹤0.01% | 4888 |
|
|
2017
Q1 | – | Sell |
-43
| Closed | -$9K | – | 6569 |
|
|
2016
Q4 | $9K | Buy |
+43
| New | +$8.62K | ﹤0.01% | 5841 |
|
|
2015
Q1 | – | Sell |
-3
| Closed | -$1K | – | 6417 |
|
|
2014
Q4 | $1K | Buy |
+3
| New | +$953 | ﹤0.01% | 6117 |
|
Other funds holding DMK
Wells Fargo's DMK Position: Q1 2024 in Review
Wells Fargo sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 214 shares — an estimated $149 sold.
Wells Fargo first reported a position in DMK in Q4 2014 and held it in 29 quarters. The position peaked at $169K in Q2 2017. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.
- Wells Fargo reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
- Wells Fargo sold 214 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $149.
- Wells Fargo first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2014 and held it in 29 quarters.
- Wells Fargo's DMK Pharmaceuticals Corporation Common Stock position peaked at $169K in Q2 2017.
- 3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.
Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.